Dyne Therapeutics (NASDAQ:DYN) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Dyne Therapeutics (NASDAQ:DYN) from a hold rating to a sell rating in a report published on Sunday morning.

Several other equities analysts have also commented on DYN. Chardan Capital reiterated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. Tudor Pickering set a $23.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, November 14th. Evercore ISI cut their price objective on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Finally, Oppenheimer upgraded shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $11.00 to $40.00 in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.47.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $20.04 on Friday. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $26.22. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a market cap of $2.86 billion, a P/E ratio of -5.48 and a beta of 1.30. The firm’s fifty day moving average price is $20.17 and its 200-day moving average price is $14.74.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.05. On average, equities research analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in Dyne Therapeutics by 64.4% during the 1st quarter. Invesco Ltd. now owns 66,293 shares of the company’s stock valued at $693,000 after purchasing an additional 25,970 shares during the period. Hsbc Holdings PLC boosted its position in shares of Dyne Therapeutics by 112.6% during the first quarter. Hsbc Holdings PLC now owns 28,396 shares of the company’s stock valued at $286,000 after purchasing an additional 15,042 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $171,000. Comerica Bank grew its stake in Dyne Therapeutics by 16.3% in the first quarter. Comerica Bank now owns 41,176 shares of the company’s stock worth $431,000 after purchasing an additional 5,767 shares during the period. Finally, Trexquant Investment LP boosted its holdings in shares of Dyne Therapeutics by 166.7% during the 1st quarter. Trexquant Investment LP now owns 334,443 shares of the company’s stock valued at $3,498,000 after buying an additional 209,065 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.